Leadership Team

Chief Executive Officer, Co-Founder

 Alex served previously as Evergreen Theragnostics' CFO, overseeing the finance function and CDMO business operations, and aided the $1B+ sale to Lantheus Holdings in 2025 (NASDAQ: LNTH). Previously he was the VP, Controller, and Interim-CFO at Blue Foundry Bancorp, a $2B bank, leading the accounting function in their 2021 IPO raising $277MM (NASDAQ: BLFY). He began his career in the audit practice of KPMG 

Director of Manufacturing Operations & Radiation Safety Officer, Co-Founder

Kyle has extensive experience in radiopharmaceutical manufacturing, nuclear pharmacy operations, and clinical pharmacy. Prior roles include VP of Manufacturing, Site Head, and Radiation Safety Officer at Evergreen Theragnostics, Facility Manager and Radiopharmacist at SOFIE, and Pharmacy Manager at CVS Health. He holds a Doctor of Pharmacy degree from MCPHS University and a Masters in Radiation Health Physics from Oregon State University.

Advisor, Co-Founder

Dr. Lyashchenko is a faculty member of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College. He oversees the Radiochemistry and Molecular Imaging Probe Core at MSKCC and has translated 50+ agents. He was a co-founder of Evergreen Theragnostics and serves as advisor to the IAEA and WHO to enhance global radiopharmaceutical access. 

Advisor, Co-Founder

Sharon is a seasoned serial entrepreneur with over 25 years in the nuclear medicine industry. He is the CEO of Marshall Isotopes and a board member of Evergreen Theragnostics. He has founded and led numerous companies across diverse industries while actively investing in innovative startup technology ventures.